The sustainability of drug development desperately depends on new models of innovation
Waltham, MA (PRWEB) May 06, 2011
Culminating 18 months of research, development and testing, OpenClinica will formally unveil a new version of its innovative software package—Version 3.1—at its Global Conference in Boston on May 8-9. This release represents a significant milestone in bringing innovative open source based technology to enhance clinical trials.
Ben Baumann, OpenClinica’s Co-Founder and Director of Business Development, says the Conference will feature a number of demonstration sessions designed to give attendees a live, hands-on experience with the new technology.
OpenClinica is the worldwide leader in providing open source clinical trials software. It facilitates the development of new medical treatments by lowering the cost of clinical trials while raising the standards for efficiency and transparency in clinical research.
The OpenClinica Global Conference brings together users, developers, and other stakeholders from the OpenClinica community to share knowledge and best practices. The event features lectures, case studies, tutorials, panel discussions, posters, and technical demonstrations. Participants in the event represent numerous countries including China, Brazil, Germany, India, Denmark, Taiwan, Austria, Switzerland, Argentina, and the United Kingdom. Participants represent biopharmaceutical companies, device companies, contract research organizations, academic centers, and government agencies.
Kenneth A. Getz, Chairman of the Center for Information & Study on Clinical Research Participation CISCRP, and Senior Research Fellow and Assistant Research Professor at the Tufts Center for the Study of Drug Development, will be the conference’s keynote speaker. He will discuss how open source software and open communities can be a solution to challenges facing the pharmaceutical industry.
“The sustainability of drug development desperately depends on new models of innovation,” said Mr. Getz. “Innovative open source projects like OpenClinica hold tremendous promise for addressing this need,” Getz said.
Because of its commercial open source licensing model, OpenClinica stands alone as the most flexible, cost effective solution for clinical trial electronic data capture (EDC) and clinical data management. The commercial version, OpenClinica Enterprise, offers advanced capabilities, regulatory compliance, and support for mission critical operations.
Several hundred health science organizations worldwide use the OpenClinica software to power their clinical trials. The community of OpenClinica users, developers and practitioners now exceeds 12,000.
The OpenClinica Global Conference is being held at the Metro Meeting Centers at101 Federal Street in downtown Boston.
OpenClinica enhances the productivity of clinical trials through commercial open source software. Trusted by hundreds of biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, the OpenClinica software facilitates electronic data capture and data management, increasing the speed of collection and quality of data in clinical trials. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. For more information – including product downloads – visit http://www.openclinica.com or follow @OpenClinica on Twitter.